Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul;116(2):379-86.
doi: 10.1007/s10549-008-0153-8. Epub 2008 Aug 14.

BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research

Susan L Neuhausen  1 , Hilmi Ozcelik, Melissa C Southey, Esther M John, Andrew K Godwin, Wendy Chung, Jeniffer Iriondo-Perez, Alexander Miron, Regina M Santella, Alice Whittemore, Irene L Andrulis, Saundra S Buys, Mary B Daly, John L Hopper, Daniela Seminara, Ruby T Senie, Mary Beth Terry; Breast Cancer Family Registry
Affiliations

BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research

Susan L Neuhausen et al. Breast Cancer Res Treat. 2009 Jul.

Abstract

The Breast Cancer Family Registry is a resource for interdisciplinary and translational studies of the genetic epidemiology of breast cancer. This resource is available to researchers worldwide for collaborative studies. Herein, we report the results of testing for germline mutations in BRCA1 and BRCA2. We have tested 4,531 probands for mutations in BRCA1 and 4,084 in BRCA2. Deleterious mutations in BRCA1 and BRCA2 were identified for 9.8% of probands tested [233/4,531 (5.1%) for BRCA1 and 193/4,084 (4.7%) for BRCA2]. Of 1,385 Ashkenazi Jewish women tested for only the three founder mutations, 17.4% carried a deleterious mutation. In total, from the proband and subsequent family testing, 1,360 female mutation carriers (788 in BRCA1, 566 in BRCA2, 6 in both BRCA1 and BRCA2) have been identified. The value of the resource has been greatly enhanced by determining the germline BRCA1 and BRCA2 mutation statuses of nearly 6,000 probands.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The frequency of deleterious germline mutation types in BRCA1 and BRCA2 observed in the Breast CFR. In-frame indel refers to either insertions or deletions of nucleotides in multiples of three
Fig. 2
Fig. 2
The most common germline BRCA1 and BRCA2 mutations observed in the Breast CFR
See this image and copyright information in PMC

References

    1. John EM, Hopper JL, Beck JC, et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res. 2004;6:R375–R389. doi:10.1186/bcr801. - DOI - PMC - PubMed
    1. Apicella C, Peacock SJ, Andrews L, et al. Determinants of preferences for genetic counselling in Jewish women. Fam Cancer. 2006;5:159–167. doi:10.1007/s10689-005-3871-7. - DOI - PubMed
    1. Andrulis IL, Anton-Culver H, Beck J, et al. Comparison of DNA-and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat. 2002;20:65–73. doi:10.1002/humu.10097. - DOI - PubMed
    1. Ganguly A, Rock MJ, Prockop DJ. Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci USA. 1993;90:10325–10329. doi:10.1073/pnas.90.21.10325. - DOI - PMC - PubMed
    1. Korkko J, Annunen S, Pihlajamaa T, et al. Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. Proc Natl Acad Sci USA. 1998;95:1681–1685. doi:10.1073/pnas.95.4.1681. - DOI - PMC - PubMed

Publication types